AI Article Synopsis
- The PSA test is crucial for diagnosing and treating prostate cancer, helping to improve detection rates for lower-risk cases and better clinical staging.
- The choice of optimal biopsy strategies is still debated among scholars, particularly regarding the use of prostate cancer biomarkers for initial and repeat biopsies.
- This review highlights current advancements and the status of transrectal ultrasound-guided biopsy techniques for prostate cancer.
Article Abstract
The prostate-specific antigen (PSA) test contributes a lot to the diagnosis and treatment of prostate cancer (PCa) and, along with imaging-guided prostate biopsy, has improved the diagnosis rate of lower-risk PCa and the accuracy of its clinical staging. However, many questions and controversies remain as to the choice of optimal biopsy strategies. Scholars differ in views about how to utilize PCa-related biomarkers to optimize the detection of initial and repeat biopsies. This review focuses on the present status of and advances in transrectal ultrasound-guided biopsy for PCa.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
ultrasound-guided biopsy
8
prostate cancer
8
[transrectal ultrasound-guided
4
biopsy
4
biopsy prostate
4
cancer update]
4
update] prostate-specific
4
prostate-specific antigen
4
antigen psa
4
psa test
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!